Coronavirus Update: No Mortality Gains From Remdesivir In WHO Trial, Gilead Questions Results
Trial Involved 11,000 Patients
Executive Summary
Plus Sanofi and Translate Bio release preclinical data from their COVID-19 vaccine candidate, another entrant to the now crowded mRNA vaccine field.
You may also be interested in...
Coronavirus Notebook: Adapted Comirnaty Vaccine Under EU Review, Sanofi & GSK Laud Next-Gen Booster
Valneva expects its vaccine candidate to be approved this month. Meanwhile, the core functions of the UK’s Vaccine Taskforce are to be transferred to the UK Health Security Agency and the Office for Life Sciences.
COVID-19: EU Veklury Approval To Be Renewed Despite Opposition
A European Parliament committee has rejected an attempt to stop the European Commission from renewing the conditional approval for Gilead’s Veklury for treating COVID-19.
Pandemic Perspectives: Remdesivir, Favipiravir’s Eventful Journeys In India A Year On
COVID-19 doesn't seem to be going away any time soon and antivirals remdesivir and favipiravir remain part of the treatment armamentarium. “Safety inventories” are in place for remdesivir in India, while a key physician anticipates an uptick in the use of favipiravir amid a surge in cases in some parts of the country.